Optimal Use of Bone-Targeted Agents in Prostate Cancer

This activity is older than 12 months.

This case study has been developed with the assistance of Fred Saad, Chief of Urology and Director of Urologic Oncology at the University of Montreal Hospital Centre. This activity was supported by Amgen. 

The information within is provided for educational purposes only and is not intended as specific medical advice. Amgen does not endorse the promotion of unapproved products or indications. Any discussion about the use of a product outside of the approved product labelling is facilitated by the speaker and is not endorsed by Amgen. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient.

All characters and events depicted in this patient case simulation are entirely fictitious. Any similarity to actual events or persons, living or dead, is purely coincidental. This activity is intended only for healthcare professionals in the following countries: Australia, Hong Kong, Singapore, South Korea, Thailand, Taiwan.

Modules

• Optimal Use of Bone-Targeted Agents in Prostate Cancer